WO2007083146A3 - The treatment of cognitive and psychotic disorders - Google Patents

The treatment of cognitive and psychotic disorders Download PDF

Info

Publication number
WO2007083146A3
WO2007083146A3 PCT/GB2007/000193 GB2007000193W WO2007083146A3 WO 2007083146 A3 WO2007083146 A3 WO 2007083146A3 GB 2007000193 W GB2007000193 W GB 2007000193W WO 2007083146 A3 WO2007083146 A3 WO 2007083146A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
cognitive
psychotic disorders
psychotic
disorder
Prior art date
Application number
PCT/GB2007/000193
Other languages
French (fr)
Other versions
WO2007083146A2 (en
Inventor
Sabine Bahn
Christopher Robin Lowe
Original Assignee
Cambridge Entpr Ltd
Sabine Bahn
Christopher Robin Lowe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd, Sabine Bahn, Christopher Robin Lowe filed Critical Cambridge Entpr Ltd
Publication of WO2007083146A2 publication Critical patent/WO2007083146A2/en
Publication of WO2007083146A3 publication Critical patent/WO2007083146A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

An anti-diabetic agent such as insulin is useful for the treatment of a psychotic disorder such as a schizophrenic disorder.
PCT/GB2007/000193 2006-01-20 2007-01-22 The treatment of cognitive and psychotic disorders WO2007083146A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0601179.5 2006-01-20
GBGB0601179.5A GB0601179D0 (en) 2006-01-20 2006-01-20 Therapies for psychotic disorders

Publications (2)

Publication Number Publication Date
WO2007083146A2 WO2007083146A2 (en) 2007-07-26
WO2007083146A3 true WO2007083146A3 (en) 2007-09-13

Family

ID=36010672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/000193 WO2007083146A2 (en) 2006-01-20 2007-01-22 The treatment of cognitive and psychotic disorders

Country Status (2)

Country Link
GB (1) GB0601179D0 (en)
WO (1) WO2007083146A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8298176B2 (en) 2006-06-09 2012-10-30 Neurosystec Corporation Flow-induced delivery from a drug mass

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
CA2698992A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
WO2009155421A1 (en) * 2008-06-19 2009-12-23 Neurosystec Corporation Gacyclidine formulations
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
GB201002627D0 (en) 2010-02-16 2010-03-31 Loxbridge Res Llp Aptamer based analyte detection method
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
WO2019125878A1 (en) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039022A1 (en) * 1997-03-03 1998-09-11 1149336 Ontario Inc. Methods of using exendin and glp-1, and agonists and antagonists thereof, to affect the central nervous system
WO2004071454A2 (en) * 2003-02-13 2004-08-26 Guilford Pharmaceuticals Inc. Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
US6927214B1 (en) * 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
US20050209142A1 (en) * 2002-11-20 2005-09-22 Goran Bertilsson Compounds and methods for increasing neurogenesis
WO2006003096A1 (en) * 2004-07-02 2006-01-12 Novo Nordisk A/S Condensed thiophene derivatives and their use as cyclic glp-1 agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039022A1 (en) * 1997-03-03 1998-09-11 1149336 Ontario Inc. Methods of using exendin and glp-1, and agonists and antagonists thereof, to affect the central nervous system
US6927214B1 (en) * 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
US20050209142A1 (en) * 2002-11-20 2005-09-22 Goran Bertilsson Compounds and methods for increasing neurogenesis
WO2004071454A2 (en) * 2003-02-13 2004-08-26 Guilford Pharmaceuticals Inc. Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv
WO2006003096A1 (en) * 2004-07-02 2006-01-12 Novo Nordisk A/S Condensed thiophene derivatives and their use as cyclic glp-1 agonists

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BRAMBILLA F ET AL: "Glucose-insulin metabolism in chronic schizophrenia.", DISEASES OF THE NERVOUS SYSTEM FEB 1976, vol. 37, no. 2, February 1976 (1976-02-01), pages 98 - 103, XP009080915, ISSN: 0012-3714 *
DOELL R: "Intravenous tolbutamide test with depressive patients", PSYCHIATRIE NEUROLOGIE UND MEDIZINISCHE PSYCHOLOGIE 1979 GERMANY, vol. 31, no. 7, 1979, pages 407 - 415, XP009081134 *
HOSÁK L: "[Review of literature on the potentiation of insulin with sulfonylurea derivatives in the treatment of schizophrenia using hypoglycemic comas]", ACTIVITAS NERVOSA SUPERIOR SEP 1966, vol. 8, no. 3, September 1966 (1966-09-01), pages 308 - 315, XP009081132, ISSN: 0001-7604 *
LEON ESPINEL J H: "[Schizophrenic syndromes treated with insulin in children; our viewpoint on schizophrenia.]", REVISTA COLOMBIANA DE PEDIATRÍA Y PUERICULTURA DEC 1955, vol. 15, no. 2, December 1955 (1955-12-01), pages 105 - 140, XP001249060, ISSN: 0120-0402 *
NEWCOMER JOHN W ET AL: "Glucose-induced increase in memory performance in patients with schizophrenia", SCHIZOPHRENIA BULLETIN, vol. 25, no. 2, 1999, pages 321 - 335, XP002427717, ISSN: 0586-7614 *
PERZYNSKI J: "Comparative evaluation of insulin shock treatment in early schizophrenia beginning with neurotic-like symptoms", PSYCHIATRIA POLSKA 1986 POLAND, vol. 20, no. 6, 1986, pages 436 - 440, XP009081191 *
STONE WILLIAM S ET AL: "Glucose effects on cognition in schizophrenia.", SCHIZOPHRENIA RESEARCH 1 JUL 2003, vol. 62, no. 1-2, 1 July 2003 (2003-07-01), pages 93 - 103, XP009081185, ISSN: 0920-9964 *
WADA AKIHIKO ET AL: "New twist on neuronal insulin receptor signaling in health, disease, and therapeutics", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 99, no. 2, October 2005 (2005-10-01), pages 128 - 143, XP009081186, ISSN: 1347-8613 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8298176B2 (en) 2006-06-09 2012-10-30 Neurosystec Corporation Flow-induced delivery from a drug mass

Also Published As

Publication number Publication date
WO2007083146A2 (en) 2007-07-26
GB0601179D0 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
WO2007083146A3 (en) The treatment of cognitive and psychotic disorders
WO2007100535A3 (en) Oxyntomodulin derivatives
EP2063889A4 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
EP2369017B8 (en) Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
AU2007228570A8 (en) Treatment of CNS conditions
AU2006224295A8 (en) N- (N-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
EP1976377A4 (en) Compounds for the treatment of metabolic disorders
EP1928470A4 (en) Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders
AU2007227398A8 (en) Compounds for the treatment of spinal muscular atrophy and other uses
WO2007056681A3 (en) Methods for administering hypoglycemic agents
ZA200808963B (en) Compounds for the treatment of metabolic disorders
EP2070935A4 (en) Novel compound, composition comprising the same, and process for production of polymerizable amide
IL192852A0 (en) Compounds for the treatment of metabolic disorders
WO2009067856A8 (en) Histone deacetylase inhibitor, composition and use thereof
WO2008156701A3 (en) Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof
WO2007080149A8 (en) Treatment of stressed patients
PL2410047T3 (en) Oxidoreductase and its use for the reduction of secodione derivatives
WO2008019782A3 (en) Dispersions of nanoureas containing active ingredients
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
WO2007104485A3 (en) Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs
IL192851A0 (en) Compounds for the treatment of metabolic disorders
WO2007012870A3 (en) Use of nefopam for the treatment of affective disorders
ZA200809774B (en) Compounds for the treatment of metabolic disorders
ZA200809565B (en) 4-(2, e-dichloro-benzoylamino)-1H-pyrazole-s-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the treatment of cancer
EP1852426A4 (en) Process for production of optically active ppar-activating compound and intermediate of the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07704972

Country of ref document: EP

Kind code of ref document: A2